A Phase II trial of immunotherapy with an anti-PD-1 antibody in advanced / relapsed, Platinum - resistant Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
At a glance
- Drugs Nivolumab (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 02 Jun 2015 Results assessing durability of anti-tumor response presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 13 Feb 2015 Status changed from active, no longer recruiting to completed, as reported by University Hospital Medical Information Network - Japan.
- 14 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.